PL2590954T3 - Bisarylowe pochodne (tio)morfoliny jako modulatory S1P - Google Patents
Bisarylowe pochodne (tio)morfoliny jako modulatory S1PInfo
- Publication number
- PL2590954T3 PL2590954T3 PL11733829.3T PL11733829T PL2590954T3 PL 2590954 T3 PL2590954 T3 PL 2590954T3 PL 11733829 T PL11733829 T PL 11733829T PL 2590954 T3 PL2590954 T3 PL 2590954T3
- Authority
- PL
- Poland
- Prior art keywords
- bisaryl
- thio
- modulators
- morpholine derivatives
- morpholine
- Prior art date
Links
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical class C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36278510P | 2010-07-09 | 2010-07-09 | |
| EP10169108 | 2010-07-09 | ||
| US201161452977P | 2011-03-15 | 2011-03-15 | |
| EP11158269 | 2011-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2590954T3 true PL2590954T3 (pl) | 2016-09-30 |
Family
ID=44323383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11733829.3T PL2590954T3 (pl) | 2010-07-09 | 2011-07-08 | Bisarylowe pochodne (tio)morfoliny jako modulatory S1P |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9029371B2 (pl) |
| EP (1) | EP2590954B1 (pl) |
| JP (1) | JP5841593B2 (pl) |
| CN (1) | CN103080096B (pl) |
| AR (1) | AR082137A1 (pl) |
| CA (1) | CA2804329C (pl) |
| DK (1) | DK2590954T3 (pl) |
| ES (1) | ES2570744T3 (pl) |
| MX (1) | MX338605B (pl) |
| PL (1) | PL2590954T3 (pl) |
| TW (1) | TW201206893A (pl) |
| UY (1) | UY33495A (pl) |
| WO (1) | WO2012004375A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI522361B (zh) * | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| US8802673B2 (en) * | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| KR101631003B1 (ko) | 2012-01-12 | 2016-06-15 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체 |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| CN114728982A (zh) | 2019-10-31 | 2022-07-08 | 逃逸生物有限公司 | 固体形式的s1p-受体调节剂 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1069387A1 (ru) | 1982-07-01 | 1985-11-30 | Институт физико-органической химии и углехимии АН УССР | Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием |
| GB2228432A (en) | 1989-01-13 | 1990-08-29 | Grayston Central Services | Multi-role machine for heating and coating pipe welds. |
| JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
| JP2681589B2 (ja) | 1992-12-28 | 1997-11-26 | 日揮株式会社 | 配管溶接継手の熱処理方法 |
| JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
| GB9522845D0 (en) | 1995-11-08 | 1996-01-10 | Smithkline Beecham Plc | Novel compounds |
| JP3822680B2 (ja) | 1996-08-30 | 2006-09-20 | 新日本製鐵株式会社 | 誘導加熱された接合部の冷却方法および冷却装置 |
| JP4518587B2 (ja) * | 1998-03-09 | 2010-08-04 | 興和創薬株式会社 | ２−フェニルモルホリン誘導体 |
| MXPA02010325A (es) | 2000-04-21 | 2003-04-25 | Shionogi & Co | Derivados de oxadiazol los cuales tienen efectos anticancer. |
| FR2822727A1 (fr) | 2001-04-03 | 2002-10-04 | Gesal Ind | Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement |
| JP3649223B2 (ja) | 2003-01-08 | 2005-05-18 | 株式会社日立製作所 | 配管系の熱処理方法および熱処理装置 |
| DK1631557T3 (da) * | 2003-06-12 | 2007-05-07 | Btg Int Ltd | Cyklisk hydroxylamin som psykoaktive forbindelser |
| US20050090520A1 (en) | 2003-09-12 | 2005-04-28 | Per Lindquist | Treatment of disease or injury of the nervous system with FTY720 |
| US7550485B2 (en) * | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| JP4491334B2 (ja) | 2004-12-01 | 2010-06-30 | 日立Ｇｅニュークリア・エナジー株式会社 | 配管の熱処理方法および装置 |
| JP4599250B2 (ja) | 2005-08-10 | 2010-12-15 | 株式会社東芝 | 高周波誘導加熱時外面温度制御方法および当該制御装置 |
| JP2007063642A (ja) | 2005-09-01 | 2007-03-15 | Hitachi Ltd | 残留応力改善方法と高周波誘導加熱用コイル |
| JP2009528363A (ja) | 2006-02-28 | 2009-08-06 | ヘリコン セラピューティクス，インコーポレイテッド | Ｐｄｅ４インヒビターとしての治療用ピペラジン |
| EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| WO2008028937A1 (en) | 2006-09-08 | 2008-03-13 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| TW200838497A (en) | 2006-12-21 | 2008-10-01 | Abbott Lab | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| BRPI0806932A2 (pt) * | 2007-02-02 | 2014-05-06 | Novartis Ag | Antagonista do receptor s1p1 de cromeno |
| EP2364976B1 (en) | 2007-03-21 | 2014-10-08 | EPIX Pharmaceuticals, Inc. | S1P receptor modulating compounds and use thereof |
| CN101679274A (zh) * | 2007-04-23 | 2010-03-24 | 诺瓦提斯公司 | 具有slp受体调节活性的酞嗪及异喹啉衍生物 |
| WO2009084501A1 (ja) | 2007-12-27 | 2009-07-09 | Asahi Kasei Pharma Corporation | スルタム誘導体 |
| WO2009097567A1 (en) | 2008-01-30 | 2009-08-06 | Cephalon, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| BRPI0905849A2 (pt) | 2008-01-30 | 2015-06-30 | Cephalon Inc | Composto, composição farmacêutica e método |
| US20090321144A1 (en) | 2008-06-30 | 2009-12-31 | Wyble Kevin J | Protecting an element from excessive surface wear by localized hardening |
| UY32858A (es) * | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| CN102753155B (zh) | 2010-02-04 | 2015-11-25 | 埃斯特韦实验室有限公司 | 4-[-2-[[5-甲基-1-(2-萘基)-1h-吡唑-3-基]氧基]乙基]吗啉盐酸盐多晶型体和溶剂化物 |
| CN101812058B (zh) | 2010-04-13 | 2012-03-21 | 湖南大学 | 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用 |
-
2011
- 2011-07-07 TW TW100124110A patent/TW201206893A/zh unknown
- 2011-07-08 JP JP2013517400A patent/JP5841593B2/ja not_active Expired - Fee Related
- 2011-07-08 MX MX2013000361A patent/MX338605B/es active IP Right Grant
- 2011-07-08 WO PCT/EP2011/061590 patent/WO2012004375A1/en not_active Ceased
- 2011-07-08 PL PL11733829.3T patent/PL2590954T3/pl unknown
- 2011-07-08 EP EP11733829.3A patent/EP2590954B1/en not_active Not-in-force
- 2011-07-08 UY UY33495A patent/UY33495A/es not_active Application Discontinuation
- 2011-07-08 CA CA2804329A patent/CA2804329C/en not_active Expired - Fee Related
- 2011-07-08 US US13/808,900 patent/US9029371B2/en not_active Expired - Fee Related
- 2011-07-08 DK DK11733829.3T patent/DK2590954T3/en active
- 2011-07-08 AR ARP110102456 patent/AR082137A1/es unknown
- 2011-07-08 ES ES11733829T patent/ES2570744T3/es active Active
- 2011-07-08 CN CN201180033952.8A patent/CN103080096B/zh not_active Expired - Fee Related
-
2015
- 2015-03-23 US US14/666,089 patent/US9227960B2/en not_active Expired - Fee Related
- 2015-12-03 US US14/958,382 patent/US9662337B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012004375A1 (en) | 2012-01-12 |
| JP2013531003A (ja) | 2013-08-01 |
| MX2013000361A (es) | 2013-04-29 |
| CN103080096B (zh) | 2015-12-09 |
| US9227960B2 (en) | 2016-01-05 |
| US20130203745A1 (en) | 2013-08-08 |
| ES2570744T3 (es) | 2016-05-20 |
| DK2590954T3 (en) | 2016-05-02 |
| UY33495A (es) | 2012-01-31 |
| EP2590954A1 (en) | 2013-05-15 |
| TW201206893A (en) | 2012-02-16 |
| CA2804329A1 (en) | 2012-01-12 |
| US9029371B2 (en) | 2015-05-12 |
| US20150191457A1 (en) | 2015-07-09 |
| AR082137A1 (es) | 2012-11-14 |
| JP5841593B2 (ja) | 2016-01-13 |
| US20160151376A1 (en) | 2016-06-02 |
| MX338605B (es) | 2016-04-22 |
| EP2590954B1 (en) | 2016-04-13 |
| US9662337B2 (en) | 2017-05-30 |
| CA2804329C (en) | 2019-05-14 |
| CN103080096A (zh) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201201446B (en) | (thio)morpholine derivatives as s1p modulators | |
| EP2672823A1 (en) | S1p modulating agents | |
| IL229045A0 (en) | Compressed heterocyclic compounds as sodium channel modulators | |
| ZA201401884B (en) | New dihydroquinoline-2-one derivatives | |
| IL232267A0 (en) | Derivatives of (4-phenylimidazol-2-yl)ethylamine and the use of preparations containing them as sodium channel modulators | |
| EP2739613A4 (en) | flavonoid | |
| ZA201300153B (en) | Spiro-cyclic amine derivatives as s1p modulators | |
| PT2734499T (pt) | Derivados de merocianina | |
| SG11201401937YA (en) | New aryl-quinoline derivatives | |
| PL2714668T3 (pl) | Pochodne tiazolowe | |
| EP2670365A1 (de) | Verbesserte patellapelotte | |
| ZA201300157B (en) | Fused heterocyclic derivatives as s1p modulators | |
| ZA201306586B (en) | Thynyl derivatives as positive allosteric modulators of the mglur5 | |
| PL2590954T3 (pl) | Bisarylowe pochodne (tio)morfoliny jako modulatory S1P | |
| IL231764A (en) | History of 2-oxo-piperidinyl | |
| GB2489487B (en) | Applicator for an endoscope | |
| LU91770B1 (en) | Replacement plug | |
| EP2739476A4 (en) | RACLE | |
| AU2011900081A0 (en) | Dtp | |
| EP2681187A4 (en) | METHOD FOR REDUCING ACYLOXY SULFIDE DERIVATIVES | |
| AU2011901900A0 (en) | Motivation Aid | |
| GB201010698D0 (en) | Split boot replacement | |
| HK1188994A (en) | Novel heterocyclic derivatives | |
| PH32011000972S1 (en) | Tissue paper | |
| PH32011000975S1 (en) | Tissue paper |